Unease over genes for profit

THERE'S money to be made from the human genome. The same genes that serve as markers for everything from breast cancer to skin type have become new pointers to profit for a growing number of pathology labs. (This article points to an important trend, which ultimately, could undercut ambitious soup-to-nuts services such as 23&me or Navigenics--NG)